M&T Bank
NRIX icon

M&T Bank’s Nurix Therapeutics NRIX Stock Holding History

M&T Bank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
+9,328
New +$159K ﹤0.01% 1598

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

M&T Bank's NRIX Position: Q2 2026 in Review

M&T Bank opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 9,328 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #1598 among its holdings.

211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • M&T Bank held 9,328 shares of Nurix Therapeutics worth $226K as of Q2 2026.
  • Nurix Therapeutics was a new M&T Bank position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1598 holding.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.